Navigation Links
XTENT Announces European Regulatory Update
Date:6/12/2008

t at one or more locations. The Custom NX DES System has not been approved for sale by any regulatory authority.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing or results of its regulatory filings, the timing of responses to its regulatory filings and the timing of the commercialization of its products. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's quarterly report on Form 10-Q for the quarter ended March 31, 2008. This quarterly report was filed with the SEC on May 13, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date th
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
2. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
3. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
4. XTENT Announces First Quarter 2008 Financial Results
5. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
10. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
11. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... , Sept. 14, 2014  Amgen (NASDAQ: AMGN ) ... ystolic H eart failure treatment with the ... T rial) study evaluating ivabradine in patients with chronic ... Annual Scientific Meeting of the Heart Failure Society of America ... analysis from the SHIFT study confirmed low systolic blood pressure ...
(Date:9/14/2014)... Sept. 14, 2014  Abbott announced today positive ... first prospective, randomized, controlled trial comparing the safety ... to Abbott,s market-leading metallic XIENCE family of DES.  ... , included 501 people with coronary artery ... disease. The results were featured at a late-breaking ...
(Date:9/13/2014)... , Sept. 13, 2014  Edwards Lifesciences ... leader in the science of heart valves and ... clinical outcomes for inoperable patients treated in The ... for transcatheter aortic valve replacement (TAVR) in patients ... were presented as part of the late-breaking clinical ...
Breaking Medicine Technology:Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 2Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 3Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 4Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 5Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 6Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 7Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 8Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 2ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 3ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 4ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 5Significant Patient Benefits With Edwards Sapien Valve Demonstrated In 5-Year Partner Trial Data 2
... Sanmina-SCI Corporation (Nasdaq: SANM ), a ... world,s most complex and valuable electronic and mechanical ... has been awarded ISO 13485 certification for medical ... manufacturing capabilities, and the company,s focus on meeting ...
... Sept. 8, 2011 Marshall Edwards, Inc. (Nasdaq: ... clinical development of novel therapeutics targeting cancer metabolism, announced ... of the Company,s lead drug candidate ME-143 in patients ... in collaboration with the Sarah Cannon Research Institute in ...
Cached Medicine Technology:Sanmina-SCI Kenosha, Wisconsin Facility Awarded ISO 13485 Certification for Medical Devices 2Sanmina-SCI Kenosha, Wisconsin Facility Awarded ISO 13485 Certification for Medical Devices 3Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3
(Date:9/14/2014)... UWDress.com, is an internationally well-known designer and ... its new range of cocktail dresses under $100 ... to worldwide ladies, the company is also providing big ... blue evening gowns, black formal gowns and so on. ... , The company’s senior spokesman says, “We are ...
(Date:9/13/2014)... 13, 2014 Ticket Down is ... tickets. This beloved pop-rock group that originally formed in 1994 ... album. Fans of the group had been anticipating a new ... fans were excited yet about the release of their new ... has announced a massive worldwide tour beginning in the United ...
(Date:9/13/2014)... Termlifeinsurancequotesonline.org has released a new ... for smokers. , Smokers can now find affordable ... examination. The only application process clients have to go ... few medical questions. , Since smoking will increase ... making a decision. Comparing life insurance policies is now ...
(Date:9/13/2014)... September 13, 2014 Bedros Keuilian, founder of ... fitness marketing coach , has always been an advocate of ... most useful days are over, but the post explains that ... need to change. , “A lot of people think of ... says Keuilian. “They run a special and the only thing ...
(Date:9/13/2014)... (PRWEB) September 13, 2014 Gainesville ... the community to their official Grand Opening celebration today, ... part of the international Fit Body Boot Camp franchise, ... workouts designed to get busy people the fast results ... , “Our workouts are hard work, but we make ...
Breaking Medicine News(10 mins):Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Smokers Can Qualify for Life Insurance Without Taking a Medical Exam 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 3Health News:Gainesville Fit Body Boot Camp Announces Grand Opening of New Fitness Boot Camp 2Health News:Gainesville Fit Body Boot Camp Announces Grand Opening of New Fitness Boot Camp 3
... Reporter , THURSDAY, June 23 (HealthDay News) -- After suffering ... hopes and fears about the future are less depressed and ... In fact, 48 percent of the people who participated ... stroke were not depressed a year later, compared to 37.7 ...
... stress appears to enhance the lung-damaging effects of traffic-related ... the Keck School of Medicine of the University of ... will appear online ahead of the print edition of ... and Critical Care Medicine . "This is the ...
... team led by Johns Hopkins researchers has found that a ... with abnormally dense blood vessel growth in the skin lining ... of Familial Cancer , could lead to a quick ... DNA tests and colonoscopies, and sometimes goes unnoticed until cancer ...
... News) -- Among heart attack patients, black Americans generally ... restore blood flow to their hearts, according to a ... hospital quality, not the race of individual patients, the ... attack patients who arrive at hospitals that aren,t equipped ...
... media use, encouraging infants and young children in preschool ... active play, and requiring child care providers to promote ... to curb high rates of obesity among America,s youngest ... Medicine. The report recommends steps that ...
... the Georgia Tech Research Institute (GTRI) have developed a ... disease and certain other neurological conditions to use the ... tremors and relay the results to medical personnel. ... replace subjective tests now used to assess the severity ...
Cached Medicine News:Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 3Health News:Exposure to parental stress increases pollution-related lung damage in children 2Health News:Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth 2Health News:Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth 3Health News:Hospital Delays Tied to Racial Divide in Heart Attack Care 2Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 2Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 3Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 4Health News:New application for iPhone may support monitoring and research on Parkinson's disease 2Health News:New application for iPhone may support monitoring and research on Parkinson's disease 3
Flattened 13 mm "Graefe type" hook, with 1.5 mm oval hole. Flat serrated handle with polished finish. Overall length: 5.6 inches....
Fine short working end. Overall length: 4.9 inches. Most popular size or model....
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall ...
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
Medicine Products: